Oil India Stock Update: Structural derating, Retain Hold
Oil India Stock Update: Structural derating; PT revised down to Rs360; Retain Hold. Ad valorem CESS to relieve OIL now but gains restricted, in case of crude price recovery: In Union Budget 2016-17, the government has changed the structure of the cess on oil production from a fixed rate of Rs4,500/metric tonne to ad valorem (at 20% of crude oil price).
Tech Mahindra arm’s new IRIS improves recharge experience in consumers
Tech Mahindra’s subsidiary Mahindra Comviva has launched IRIS, the newest addition to its Revenue Plus suite - a monetization platform for CSPs. Comviva explains that Incremental Revenues through Incremental Sales (IRIS) unifies retailer and subscriber recharge processes by providing a seamless, congruent and concurrent recharge experience to both the parties. IRIS gives the flexibility of treating each customer and retailer differently and rewards their unique combination at various levels of the upgrade.
Asian Paints operations at paints plant in Rohtak restarts
Asian Paints operations at its paints plant in Rohtak restarts; operation was closed for just 10 days – don’t expect any material impact on sales. Asian Paints operations at its paint Plant situated at Rohtak, Haryana, have restarted. The unit has manufacturing capacity of 2 lakh kilo litre per annum. Since the operation were closed from February 22nd 2016, the company loss the production for just 10 days. We don’t expect it to have any material impact on the sales and earnings of the company.
RComm: Disagreement with TPG group over valuation of tower assets
Reliance Communications: Disagreement with TPG group over valuation of tower assets, valued tower assets at Rs15000 crore vs earlier valuation of 21500 crore, negative read-thru. As per media news, TPG and Tillman Global Holdings LLC have signalled that they view the assets as worth about Rs15,000 crore, including debt, after conducting due diligence on Reliance Communications Ltd’s tower assets, down from the R.21,500 crore proposed earlier in the negotiations. Reliance Communications said that the bidders have not reduced the enterprise value for the tower business by that amount
Cipla: Delays and lack of clarity are growing concerns
Cipla: Delays and lack of clarity on launch timeline of inhalers in US market are growing concerns. Event: Mylan recently announced that its abbreviated new drug applications (ANDAs) for fluticasone propionate 100, 250, 500mcg and salmeterol 50mcg inhalation powder have been accepted for filing by the US Food and Drug Administration (USFDA). The USFDA has provided Mylan a goal date of March 28, 2017 (meaning if the product is approved under a standard review period, generic Advair could be launched in 2017). Mylan has now become the third generic player to file for generic Advair after Sandoz and Hikma.
We Are Providing Live Market Update, Market Research Report, Equity & Commodity Trading Calls With 2 Days Free Trial..